Sequential RAS Mutations Evaluation in Cell-free DNA of Patients with Tissue RAS Wild-type Metastatic Colorectal Cancer: the PERSEIDA (Cohort 2) Study

Purpose: RAS (KRAS/NRAS) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is essential in guiding the optimal treatment decision for mCRC. RAS mutations are negative predictive factors for the use of EGFR monoclonal antibodies. Cell-free DNA (cfDNA) analysis enables minimally invasive monitoring of tumor evolution.

Methods/patients: PERSEIDA was an observational, prospective study assessing cfDNA RAS, BRAF and EGFR mutations (using Idylla™) in first-line mCRC, RAS wild-type (baseline tumor-tissue biopsy) patients (cohort 2). Plasma samples were collected before first-line treatment, after 20 ± 2 weeks, and at disease progression.

Results: 117 patients were included (103 received panitumumab + chemotherapy as first-line treatment). At baseline, 7 (6.8%) patients had RAS mutations, 4 (3.9%) BRAF mutations and no EGFR mutations were detected (cfDNA, panitumumab + chemotherapy subpopulation [panitumumab + Ch]). The baseline RAS mutational status concordance between tissue and liquid biopsies was 94.0% (93.2%, panitumumab + Ch). At 20 weeks, only one patient in the study (included in the panitumumab + Ch) had an emerging cfDNA RAS mutation. No emerging BRAF or EGFR mutations were reported. At disease progression, 6 patients had emergent mutations not present at baseline (RAS conversion rate: 13.3% [6/45]; 15.0% [6/40], panitumumab + Ch).

Conclusions: The concordance rate between liquid and solid biopsies at baseline was very high, as previously reported, while our results suggest a considerable emergence of RAS mutations during disease progression. Thus, the dynamics of the genomic landscape in ctDNA may provide relevant information for the management of mCRC patients.

References

Cervantes A, Martinelli E . Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol. 2023; 35(2):241-243. DOI: 10.1016/j.annonc.2023.10.129. View

Obermannova R, Van Cutsem E, Yoshino T, Bodoky G, Prausova J, Garcia-Carbonero R . Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016; 27(11):2082-2090. PMC: 5091322. DOI: 10.1093/annonc/mdw402. View

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M . Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18(2):221-3. DOI: 10.1038/nm.2609. View

Maurel J, Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M . Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy. JCO Precis Oncol. 2022; 3:1-16. DOI: 10.1200/PO.18.00289. View

Li J, Hu M, Liu N, Li H, Yu Z, Yan Q . Correction to: HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFβ axis. J Exp Clin Cancer Res. 2022; 40(1):404. PMC: 8719399. DOI: 10.1186/s13046-021-02232-x. View

Takayama Y, Suzuki K, Muto Y, Ichida K, Fukui T, Kakizawa N . Monitoring circulating tumor DNA revealed dynamic changes in status in patients with metastatic colorectal cancer. Oncotarget. 2018; 9(36):24398-24413. PMC: 5966256. DOI: 10.18632/oncotarget.25309. View

Cooke J, Sullivan M, Gal-Yam A, Barton E, Carlberg R, Ryan-Weber E . Superluminous supernovae at redshifts of 2.05 and 3.90. Nature. 2012; 491(7423):228-31. DOI: 10.1038/nature11521. View

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R . Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clin Cancer Res. 2023; 29(12):2250-2265. PMC: 10261919. DOI: 10.1158/1078-0432.CCR-22-3298. View

10.

Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T . Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol. 2020; 26(3):494-506. PMC: 7895797. DOI: 10.1007/s10147-020-01829-0. View

11.

Valladares-Ayerbes M, Garcia-Alfonso P, Munoz Luengo J, Pimentel Caceres P, Castillo Trujillo O, Vidal-Tocino R . Evolution of Mutations in Cell-Free DNA of Patients with Tissue Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study. Cancers (Basel). 2022; 14(24). PMC: 9776941. DOI: 10.3390/cancers14246075. View

12.

Diehl F, Li M, He Y, Kinzler K, Vogelstein B, Dressman D . BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006; 3(7):551-9. DOI: 10.1038/nmeth898. View

13.

Peeters M, Kafatos G, Taylor A, Gastanaga V, Oliner K, Hechmati G . Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 2015; 51(13):1704-13. DOI: 10.1016/j.ejca.2015.05.017. View

14.

Huynh M, Hobbs G, Schaefer A, Pierobon M, Carey L, Diehl J . Functional and biological heterogeneity of KRAS mutations. Sci Signal. 2022; 15(746):eabn2694. PMC: 9534304. DOI: 10.1126/scisignal.abn2694. View

15.

Parseghian C, Sun R, Woods M, Napolitano S, Lee H, Alshenaifi J . Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol. 2022; 41(3):460-471. PMC: 9870238. DOI: 10.1200/JCO.22.01423. View

16.

Gazzaniga P, Raimondi C, Urbano F, Cortesi E . EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment. JCO Precis Oncol. 2022; 2:1-6. DOI: 10.1200/PO.17.00277. View

17.

Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V . Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014; 6(249):249ra111. PMC: 4399712. DOI: 10.1126/scitranslmed.3008982. View

18.

Scarabino D, Veneziano L, Mantuano E, Arisi I, Fiore A, Frontali M . Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study. Int J Mol Sci. 2022; 23(21). PMC: 9654348. DOI: 10.3390/ijms232113449. View

19.

Heitzer E, Haque I, Roberts C, Speicher M . Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2018; 20(2):71-88. DOI: 10.1038/s41576-018-0071-5. View

20.

Guenther M, Haas M, Heinemann V, Kruger S, Westphalen C, von Bergwelt-Baildon M . Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study. Br J Cancer. 2021; 125(3):466. PMC: 8329067. DOI: 10.1038/s41416-021-01447-1. View